Where The Selling Ran Deepest: 31 Stocks At 52-Week Lows

Large, established companies are hitting new lows, raising questions about the difference between price and business performance.

The Pharmaceuticals industry placed the most names on today's 52-week-low list, with 3 companies hitting their weakest price of the past year. In total, 31 US and Canada-listed stocks with a market value above $500 million made the screen. The largest is TJX Companies (TJX), with a market value of about $142.6 billion, and its stock has declined 19.9% over the last month.

That one-month slide compares to a return of -0.9% for the S&P 500 (SPY) over the same period. When giants like TJX and the second-largest name on the list, Stryker (SYK), are hitting new lows, the central question is what to make of the disconnect between price and performance. The full list follows.

The Complete 52-Week-Low List

The table below lists all 31 US and Canada-listed stocks in the Trefis coverage universe at their 52-week lows (the screen only considers companies with market values above $500 million), largest first, with one-day, one-week, one-month, and one-year returns:

Are these businesses as weak as their stock prices?

Two of the largest names on the list show a notable contrast between their recent stock declines and their recent business results. TJX Companies (TJX) saw its stock fall 19.9% over the last month, yet its revenue grew 7.7% over the last twelve months. Similarly, Stryker (SYK) stock declined 18.5% over the last month, while its revenue grew 8.5% over the last twelve months. These figures highlight that a stock's yearly low does not always coincide with a shrinking business.

A low price is a signal, not a verdict.

A 52-week-low list is a tool for discovery, not a simple shopping list. A stock at its weakest price in a year can mark a business with genuine fundamental damage, or it can mark a solid business that has simply been marked down by the market. The disciplined move is to treat the low as a prompt to check the business itself before reacting to the price alone.

A 52-week-low list tells you where the pain is; it does not tell you which of these declines are worth buying. That second question is what our Buy the Dip screen answers, every day: beaten-down names where the fundamentals still hold up.

The Low List Is A Symptom. Own The Discipline Instead

Stocks land on this list for different reasons, and the businesses behind them are in very different shape; what they share is that the market's verdict arrived faster than any of them could answer it. Some will answer it in time and some will not, and telling them apart name by name is unforgiving work.

That work is what the Trefis High Quality (HQ) Portfolio systematizes: about 30 quality businesses screened for the cash flow and balance-sheet strength that let a company fight through a bad year, sized and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000. Read the list; own the discipline.